In Brief: Merck's Fosamax
Executive Summary
Merck's Fosamax: Wyeth-Ayerst and Merck enter into a co-promotion agreement under which Wyeth would promote the osteoporosis treatment to U.S. obstetricians and gynecologists when the agent is approved by FDA, Merck announces June 19. Merck would market the product to other key specialty groups such as endocrinologists, rheumatologists and primary care physicians. The Fosamax (alendronate) NDA will be reviewed by an FDA advisory committee on July 13 ("The Pink Sheet" June 19, T&G-6)...